Read more stories about
Montana Biotech >>

MATR Sponsor:

MATR Supporters:

S.F. biotech has equity funding epiphany. Firm embracing new model for raising capital

March 31, 2007View for printing

Epiphany Biosciences said it raised $36 million in a private equity round, but management likes to focus less on how much was raised than from whom.

For the San Francisco company's A round, Epiphany decided to bypass traditional life science venture investors to opt instead for lead investor Wexford Capital LLC, a private equity firm in Greenwich, Conn.

San Francisco Business Times - March 23, 2007 by Daniel S. Levine

Full Story: ... 600^1436328
No reader comments so far. Be the first to comment by clicking the button below.

Reprinted under the Fair Use doctrine of international copyright law. Full copyright retained by the original publication. In accordance with Title 17 U.S.C. Section 107, this material is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes.

E-mail this page to a friend!